Relevance of treatment compliance in heart failure;Importancia del cumplimiento terapéutico en la insuficiencia cardíaca

Medicina Clinica

Volumn 124, Issue 8, 2005, Pages 302-307

  Conthe, Pedro ^a   Visús, Eva ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Heart failure; Relevance; Therapeutic compliance

Indexed keywords

NEUROHORMONE; NEUROHORMONE INHIBITOR; UNCLASSIFIED DRUG;

COST CONTROL; DOCTOR PATIENT RELATION; DRUG EFFICACY; DRUG WITHDRAWAL; FOLLOW UP; HEALTH CARE COST; HEALTH EDUCATION; HEALTH SURVEY; HEART FAILURE; HOSPITALIZATION; HUMAN; PATIENT COMPLIANCE; PHARMACOLOGICAL THERAPEUTIC ADHERENCE; PILL; PROGNOSIS; RELIABILITY; REVIEW; RISK FACTOR; SIDE EFFECT; SOCIAL ISOLATION;

EID: 16444379593     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13072325     Document Type: Review

References (48)

1. WHO Adherence to Long Term Therapies Project II. Global Adherence Interdisciplinary Network. World Health Organization; 2003; ISBN 92 4 154599 2.
2. Sorensen TI. The changing lifestyle in the world. Body weight and what else? Diabetes Care. 2000;23:1B-4B.
3. Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther. 1999;21:1074-90.
4. McInnes GT. Integrated approaches to management of hypertension: promoting treatment acceptance. Am Heart Journal. 1999;138:252S-5S.
5. Christensen DB, Williams B, Goldberg HI, Martin DP, Engelberg R, LoGerfo JP. Assessing compliance to hypertensive medications using computer-based pharmacy records. Med Care. 1997;35:1252-62.
6. Caro JJ, Salas M, Raggio G, Jackson JD. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. CMAJ. 1999;160:41-6.
7. Bailey WC, Richards JM Jr, Brooks CM, Soong SJ, Windsor RA, Manzella BA. A randomized trial to improve self-management practices of adults with asthma. Arch Intern Med. 1990;150:1654-8.
8. Faulkner MA, Wadibia EC, Lucas BD, Hilleman DE. Impact of pharmacy counseling on compliance and effectiveness of combination lipidlowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial. Pharmacotherapy. 2000;20:410-6.
9. Kavanagh DJ, Gooley S, Wilson PH. Prediction of adherence and control in diabetes. J Behav Med. 1993;6:509-22.
10. Somons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid lowering drugs. Med J Austr. 1996;164:208-11.
11. Márquez Contreras E, Casado Martínez JJ. El incumplimiento farmacológico en las enfermedades cardiovasculares. Med Clin (Barc). 2001;116 Supl 2:46-51.
12. Roter DL, Hall JA, Merisca R, Nordstrom B, Cretin D, Svarstad B. Effetiveness of interventions to improve patient compliance: a metaanalysis. Med Care. 1998;36:1138-61.
13. Gans KM, Lapane KL, Lasater TM, Carleton RA. Effect of intervention on compliance to referral and lifestyle recommendations given at cholesterol screening programs. Am J Prev Med. 1994;10:275-82.
14. Raynor OK, Booth TG, Blenkinsopp A. Effects of computer generated remindercharts on patients' compliance with drug regimens. BMJ. 1993;306:1158-61.
15. Lowe CJ, Raynor DK, Courtney EA, Purvis J, Teale C. Effects of self medication program on knowledge of drugs and compliance with treatment in elderly patients. BMJ. 1995;310:1229-31.
16. Cegala DJ, Marinelli T, Post D. The effects of patient communication skills training on compliance. Arch Fam Med. 2000;9:57-64.
17. Remme WJ, Swedberg K. The Task Force on Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J. 2001;22:1527-60.
18. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002;347:1397-402.
19. Rizzo JA, Simons WR. Variations in compliance among hypertensive patients by drug class: implications for health care costs. Clin Ther. 1996;19:1446-57.
20. Puigventos Latorre F, Llodrá Ortolá V, Vilanova Boltó M, Delgado Sánchez O, Lázaro Ferreruela M, Forteza-Rey Borrallerás J et al. Cumplimiento terapéutico en el tratamiento de la hipertensión: 10 años de publicaciones en España. Med Clin (Barc). 1997;109:702-6.
21. Márquez Contreras E, Casado Martínez JJ, Ramos Gómez J, Sáenz Soubrier S, Moreno García JP, Celotti Gómez B, et al. Influencia del cumplimiento terapéutico en los niveles de presión arterial en el tratamiento de la hipertensión arterial. Hipertensión. 1998;15:133-9.
22. Márquez Contreras E, Casado Martínez JJ, Martinez Vázquez M, Moreno García JP, Fernández Ortega A, Villar Ortiz J, et al. Análisis de la influencia del cumplimiento terapéutico farmacológico, en las presiones arteriales y grado de control de la HTA, mediante monitorización ambulatoria de la presión arterial. Med Clin (Barc). 2001;116 Supl 2:114-21.
23. Márquez Contreras E, Casado Martínez JJ, López de Andrés M, Corés Prieto E, López Zamorano JM, Moreno García JP, et al. Cumplimiento terapéutico de las dislipemias. Ensayo sobre la eficacia de la educación sanitaria. Aten Primaria. 1998;22:79-84.
24. Gil VF, Belda J, Piñeiro F, Merino J. Métodos para medir el cumplimiento. En: Gil VF, Belda J, Piñeiro F, Merino J, editores. El cumplimiento terapéutico. Madrid: Doyma; 1999. p. 77-90
25. McKenney JM, Munroe WP, Wright JT. Impact of an electronic medication compliance aid on long-term blood pressure control. J Clin Pharmacol. 1992;32:277-83.
26. Márquez E, Casado JJ, Márquez JJ. Estrategias para mejorar el cumplimiento terapéutico. FMC. 2001;8:558-73.
27. Grupo de trabajo de IC de la SEMI. La IC en los Servicios de M.Interna en España. Registro SEMI-IC. Med Clin (Barc). 2002;118:605-10.
28. García Alegría J. Estudio CIAC: Calidad de Informes al alta hospitalaria. Congreso Mundial de Medicina Interna. Granada; septiembre de 2004.
29. Hunt HA, Baker DW, Chin MH, Cinquegrani MP, Feldmanmd AM, Francis GS, et al. American College of Cardiology/American Heart Association Guidelines for the Evaluation and Management of Chronic Heart Failure in the adult. Circulation. 2001;104:2996-3007.
30. Heart failure: evaluation and care of patients with left-ventricular dysfunction. Maryland: US Department of Health and Human Services. Publication n.° 94-0612, 1994.
31. Kannel WB, Wilson WF. An update on coronary risk factors. Med Clin North Am. 1995;79:951-7.
32. Moser M, Hebert PR. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol. 1996;27:1214-8.
33. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, et al. Blood pressure, stroke, and coronary heart disease (II). Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiologicalcontext. Lancet. 1990;335:827-38.
34. Cleland JG, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar and Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The EuroHeart Failure survey programme: a survey on the quality of care among patients with heart failure in Europe (I): patient characteristics and diagnosis. Eur Heart J. 2003;24:442-63.
35. Chui MA, Deer M, Bennett SJ, Tu W, Oury S, Brater DC, et al. Association between adherence to diuretic therapy and health care utilization in patients with heart failure. Pharmacotherapy. 2003;23:326-32.
36. Gonzalez B, Lupon J, Parajon T, Urrutia A, Altimir S, Coll R, et al. Nurse evaluation of patients in a new multidisciplinary Heart Failure Unit in Spain. Eur J Cardiovasc Nurs. 2004;3:61-9.
37. Home R, Weinman J. Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res. 1999;47:555-67.
38. Remme WJ, McMurray J, Rauch B, Zannad F, Keukelaar K, Cohen A, for the SHAPE Study Heart Failure Awareness and Perception in Europe: a Pan-European general public survey on awareness and perception of the clinical, social and economic importance of heart failure in the community. ESC Congress, septiembre; 2003.
39. Bohachick P, Burke LE, Sereika S, Murali S, Dunbar-Jacob J. Adherence to angiotensin-converting enzyme inhibitor therapy for heart failure. Prog Cardiovasc Nurs. 2002;17:160-6.
40. Struthers AD, Anderson G, MacFadyen RJ, Fraser C, MacDonald TM. Non-adherence with ACE inhibitor treatment is common in heart failure and can be detected by routine serum ACE activity assays. Heart. 1999;82:584-5.
41. Struthers AD, MacFadyen R, Fraser C, Robson J, Morton JJ, Junot C, et al. Nonadherence with angiotensin-converting enzyme inhibitor therapy: a comparison of different ways of measuring it in patients with chronic heart failure. J Am Coll Cardiol. 1999;34:2072-7.
42. Ni H, Nauman D, Burgess D, Wise K, Crispell K, Hershberger RE. Factors influencing knowledge of and adherence to self-care among patients with heart failure. Arch Intern Med. 1999;159:1613-9.
43. Hobbs R. Can heart failure be diagnosed in primary care? BMJ. 2000;321:188-9.
44. Bloom B S. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther. 1998;20:671-81.
45. Grupo de Trabajo de Insuficiencia Cardíaca de la SEMI, Insuficiencia cardíaca: recomendaciones diagnósticas y terapéuticas de la Sociedad Española de Medicina Interna. Madrid: Jarpyo: 2002.
46. Cleland JG, Gemmell I, Khand A, Boddy A. Is the prognosis of heart failure improving? Eur J Heart Fail. 1999;1:229-41.
47. Management of chronic heart failure in adults in primary and secondary care. National Institute for Clinical Excellence Nice Guide Heart Failure NHS. Londres, julio de 2003.
48. Hlatky MA. Evidence-based use of cardiac procedures and devices; N Engl J Med. 2004;350:2126-8.